The risk of prevalent LOH according to quartiles of LAP
| LOH | Quartile 1 (–28.9 to 17.1) | Quartile 2 (17.2–29.1) | Quartile 3 (29.2–46.9) | Quartile 4 (47.0–488.0) | One quartile increase of LAP |
| Model 1 | 1 | 1.69 (0.73–3.93) | 3.00 (1.37–6.57) | 5.88 (2.81–12.32) | 1.83 (1.48–2.27) |
| Model 2 | 1 | 1.69 (0.73–3.95) | 3.18 (1.45–6.99) | 6.37 (3.01–13.32) | 1.88 (1.51–2.34) |
| Model 3 | 1 | 1.22 (0.51–2.91) | 2.24 (0.99–5.04) | 4.22 (1.94–9.18) | 1.71 (1.36–2.16) |
| Model 4 | 1 | 1.10 (0.45–2.69) | 2.15 (0.93–4.94) | 3.83 (1.73–8.45) | 1.67 (1.32–2.12) |
Data are ORs (95% CI). Participants without LOH are defined as 0 and with LOH as 1.
Model 1 is unadjusted.
Model 2 is adjusted for age.
Model 3 is adjusted for age, LH and SHBG.
Model 4 is adjusted for age, LH, SHBG, current smoking status and current drinking status.
LAP, lipid accumulation product; LH, luteinising hormone; LOH, late-onset hypogonadism; SHBG, sex hormone binding globulin.